Comparison of two botulinum toxin type A preparations for treating crow's feet: A split-face, double-blind, proof-of-concept study

Dermatologic Surgery

Volumn 36, Issue SUPPL. 4, 2010, Pages 2155-2160

  Prager, Welf ^a   Wissmüller, Esther ^b   Kollhorst, Bianca ^b   Williams, Stefanie ^c   Zschocke, Ina ^b  

^a DERMATOLOGIKUM HAMBURG   (Germany)

^b SCIderm GmbH   (Germany)

^c European Dermatology London   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROW FEET; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SELF EVALUATION; WRINKLE;

ADULT; BOTULINUM TOXINS, TYPE A; DOUBLE-BLIND METHOD; EYE; FEMALE; HUMANS; INJECTIONS; MALE; MIDDLE AGED; NEUROMUSCULAR AGENTS; SKIN AGING; TREATMENT OUTCOME;

EID: 78650134659     PISSN: 10760512     EISSN: 15244725     Source Type: Journal    
DOI: 10.1111/j.1524-4725.2010.01798.x     Document Type: Article

References (29)

1. Carruthers J, Fagien S, Matarasso SL, and the Botox Consensus Group. Consensus recommendations on the use of botulinum toxine type A in facial aesthetics. Plast Reconstr Surg 2004; 114 (Suppl 6): 1-22.
2. Sommer B, Bergfeld D, Sattler G., Konsensusempfehlungen zum Gebrauch von Botulinumtoxin A in der ästhetischen Medizin-Klinische Erfahrungen und Empfehlungen langjähriger Anwender. JDDG 2007; 5 (Suppl 1): 1-29.
3. Brin MF., Botulinum toxin: chemistry, pharmacology, toxicity, and immunology. Muscle Nerve 1997; 20 (Suppl 6): 146-68.
4. Fagien S., Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103: 701-3.
5. Pierard GE, Lapièr CM., The microanatomical basis of facial frown lines. Arch Dermatol 1989; 125: 1090-2.
6. Klein AW, Carruthers A, Fagien S, Lowe NJ., Comparison among botulinum toxins: an evidence-based review. Plast Reconstr Surg 2008; 121: 413e-22e.
7. Carruthers JD, Glogau RG, Blitzer A., Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type A, hyaluronic acid dermal fillers, and combination therapies-consensus recommendations. Plast Reconstr Surg 2008b; 121 (5 Suppl): 5-30.
8. Lowe NJ, Ascher B, Heckmann M, et al,. Botox Facial Aesthetic Study Team. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31: 257-62.
9. Lowe N, Lask G, Yamauchi P, et al,. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47: 834-40.
10. Matarasso SL., Comparison of botulinum toxin types A and B: a bilateral and double-blind randomized evaluation in the treatment of canthal rhytides. Dermatol Surg 2003; 29: 7-13.
11. Bigalke H., Properties of pharmaceutical products of botulinum Neurotoxins. In:, Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallett M, Mayer N, editors. Botulinum Toxin Therapeutic Clinical Practice & Science. Amsterdam: Elsevier; 2009, chapter 32.
12. Dressler D, Benneck R., Pharmacology of therapeutic botulinum toxin preparations. Disabil Rehabil 2007; 29: 1762-8.
13. Dressler D., Pharmacological aspects of therapeutic botulinum toxin preparations. Nervenarzt 2006; 77: 912-21.
14. Borodic G., Immunologic resistance after repeated botulinum toxin type A injections for facial rhytides. Ophthal Plast Reconstr Surg 2006; 22: 239-40.
15. Lee SK., Antibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophy. Dermatol Surg 2007; 33: 105-10.
16. Blümel J, Frevert J, Schwaier A., Comparative antigenicity of three preparations of botulinum neurotoxin type A in the rabbit. Neurotoxic Res 2006; 9: 238.
17. Â) in focal dystonia. Drugs 2007a; 67: 669-83. (Pubitemid 46535642)
18. Prager W, Zschocke I, Reich C, et al,. Beeinflusst die Verdünnung das kosmetische Ergebnis von BoNTA zur Behandlung der Glabellafalte. Hautarzt 2009; 10: 815-20.
19. Â) in der Behandlung der Glabellafalte. Kosmet Med 2008; 3: 36-9.
20. Â) bei der Behandlung von mimischen Falten- Untersuchungsergebnisse. Kosmet Med 2007; 2: 81-4.
21. Â) in der Therapie mimischer Lachfalten. Kosmet Med 2006; 3: 124-9.
22. Â) bei 40 Patienten. Plast Chir 2006; 6 (Suppl 1): 55.
23. Â) in focal dystonia. Mov Disord 2008; 23: 80.
24. Â): a meta-analysis. Mov Disord 2008; 23: 170.
25. Jost W., Efficacy and safety of botulinum neurotoxin type A free of complexing proteins (NT201) in cervical dystonia and blepharospasm. Future Neurol 2007; 2: 485-93.
26. Roggenkamper P, Jost WH, Bihari K, et al,. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006; 113: 303-12.
27. Benecke R, Jost WH, Kanovsky P, et al,. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005; 64: 1949-51.
28. Maack M, Krüger J, Bayrhammer J, et al,. Beeinflussen Komplexproteine das Diffusionsverhalten. Der Deutsche Dermatol 2007; 55/8: 562-3.
29. Wohlfahrt K, Kampe K, Bigalke H., Pharmakokinetic properties of different formulations of botulinum neurotoxin type A. Mov Disord 2004; 19 (Suppl 8): 65-7.